Miklós Békés (Miklos Bekes)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Estrogen Receptor

Metastatic Breast Cancer

Endoplasmic Reticulum

Top Venues

Nature structural & molecular biology

Clinical cancer research : an official journal of the American Association for Cancer Research

Science advances

Nature reviews. Drug discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher M Hickey, Katherine M Digianantonio, Kurt Zimmermann, Alicia Harbin, Connor Quinn, Avani Patel, Peter Gareiss, Amanda Chapman, Bernadette Tiberi, Jennifer Dobrodziej, John Corradi, Angela M Cacace, David R Langley, Miklós Békés
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules. Nature structural & molecular biology 31 (2) (2024)
Christopher M Hickey, Katherine M Digianantonio, Kurt Zimmermann, Alicia Harbin, Connor Quinn, Avani Patel, Peter Gareiss, Amanda Chapman, Bernadette Tiberi, Jennifer Dobrodziej, John Corradi, Angela M Cacace, David R Langley, Miklós Békés
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules. Nature structural & molecular biology 31 (2) (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Christopher M Hickey, Katherine M Digianantonio, Kurt Zimmermann, Alicia Harbin, Connor Quinn, Avani Patel, Peter Gareiss, Amanda Chapman, Bernadette Tiberi, Jennifer Dobrodziej, John Corradi, Angela M Cacace, David R Langley, Miklós Békés
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules. Nature structural & molecular biology 31 (2) (2024)
Christopher M Hickey, Katherine M Digianantonio, Kurt Zimmermann, Alicia Harbin, Connor Quinn, Avani Patel, Peter Gareiss, Amanda Chapman, Bernadette Tiberi, Jennifer Dobrodziej, John Corradi, Angela M Cacace, David R Langley, Miklós Békés
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules. Nature structural & molecular biology (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Christopher M Hickey, Katherine M Digianantonio, Kurt Zimmermann, Alicia Harbin, Connor Quinn, Avani Patel, Peter Gareiss, Amanda Chapman, Bernadette Tiberi, Jennifer Dobrodziej, John Corradi, Angela M Cacace, David R Langley, Miklós Békés
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules. Nature structural & molecular biology (2024)
Christopher M Hickey, Katherine M Digianantonio, Kurt Zimmermann, Alicia Harbin, Connor Quinn, Avani Patel, Peter Gareiss, Amanda Chapman, Bernadette Tiberi, Jennifer Dobrodziej, John Corradi, Angela M Cacace, David R Langley, Miklós Békés
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules. Nature structural & molecular biology 31 (2) (2024)
Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Miklós Békés, David R Langley, Craig M Crews
PROTAC targeted protein degraders: the past is prologue. Nature reviews. Drug discovery 21 (3) (2022)
Wioletta Rut, Zongyang Lv, Mikolaj Zmudzinski, Stephanie Patchett, Digant Nayak, Scott J Snipas, Farid El Oualid, Tony T Huang, Miklós Békés, Marcin Dra G, Shaun K Olsen
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Science advances 6 (42) (2020)